scholarly journals Management of TB/HIV co-infection: the state of the evidence

2020 ◽  
Vol 54 (3) ◽  
pp. 186-196
Author(s):  
Kwasi Torpey ◽  
Adwoa Agyei-Nkansah ◽  
Lily Ogyiri ◽  
Audrey Forson ◽  
Margaret Lartey ◽  
...  
Keyword(s):  
National Level ◽  
Hiv Treatment ◽  
The State ◽  
Sub Saharan Africa ◽  
People Living With Hiv ◽  
Increased Risk ◽  
Mdr Tb ◽  
Sub Saharan ◽  
Living With Hiv ◽  
Hiv Negative

Tuberculosis (TB) and HIV are strongly linked. There is a 19 times increased risk of developing active TB in people living with HIV than in HIV-negative people with Sub-Saharan Africa being the hardest hit region. According to the WHO, 1.3 million people died from TB, and an additional 300,000 TB-related deaths among people living with HIV. Although some progress has been made in reducing TB-related deaths among people living with HIV due to the evolution of diagnostics, treatment and antiretroviral HIV treatment, multi drug resistant TB is becoming a source of worry. Though significant progress has been made at the national level, understanding the state of the evidence and the challenges will better inform the national response of the opportunities for improved patient outcomes.Keywords: Tuberculosis, management, HIV, MDR TB, GhanaFunding: None

scholarly journals HIV Treatment in sub-Saharan Africa: Did bureaucratic headwinds delay access to dolutegravir?

2019 ◽  
Author(s):  
Reuben Granich ◽  
Somya Gupta
Keyword(s):  
Service Delivery ◽  
National Level ◽  
Essential Element ◽  
Hiv Treatment ◽  
Sub Saharan Africa ◽  
World Health ◽  
Critical Element ◽  
People Living With Hiv ◽  
Sub Saharan ◽  
Living With Hiv

IntroductionThe World Health Organization now recommends dolutegravir (DTG) as part of the preferred first-line treatment for all adults living with HIV including women who may become pregnant. The new regimen with its high barrier to resistance, shortened time to suppression, superior side effects profile, and lower health sector and individual costs, represents a significant improvement. The recommendation removes an important obstacle to accessing dolutegravir as an essential element in controlling the epidemic. DiscussionTranslating science to policy to HIV service delivery is complex and vulnerable to significant delays. WHO, assuming a regulatory role, used preliminary Botswana Tsepamo study information regarding neural tube defects to issue a “safety signal” regarding DTG in May 2018. Regulatory evaluations of rare adverse reactions are complex, take time, and require considerable subject area specific expertise. After over a year, the WHO reversed its initial findings and issued revised treatment recommendations. However, the mixed messaging and confusion around dolutegravir’s safety profile has delayed national level adoption. The pace of national adoption of new WHO recommendations is measurable through published national guidelines and/or circulars available in the public domain. After 2015, published guidelines for 22 of 46 sub-Saharan countries (94% of 2018 regional HIV burden) showed that only three countries representing 4% of regional burden have adopted the new WHO preferred 1st line recommendations. ConclusionsMonitoring and evaluating the translation of science to service delivery is a critical element of successful disease control and elimination. The DTG false alarm and ongoing delayed access provides an opportunity to learn valuable lessons and implement corrective actions. However, lessons can only be learned by accurately describing and examining the timeline, processes, and impact of policy decisions that can adversely impact millions of people living with HIV. As with any successful global disease elimination effort or major project, it is important to establish a critical pathway for translation of science to service delivery and hold people and agencies accountable for their roles in accelerating and/or delaying progress.

scholarly journals HIV Treatment in sub-Saharan Africa: Did bureaucratic headwinds delay access to dolutegravir?

2019 ◽  
Author(s):  
Reuben Granich ◽  
Somya Gupta
Keyword(s):  
Service Delivery ◽  
National Level ◽  
Essential Element ◽  
Hiv Treatment ◽  
Sub Saharan Africa ◽  
World Health ◽  
Critical Element ◽  
People Living With Hiv ◽  
Sub Saharan ◽  
Living With Hiv

IntroductionThe World Health Organization now recommends dolutegravir (DTG) as part of the preferred first-line treatment for all adults living with HIV including women who may become pregnant. The new regimen with its high barrier to resistance, shortened time to suppression, superior side effects profile, and lower health sector and individual costs, represents a significant improvement. The recommendation removes an important obstacle to accessing dolutegravir as an essential element in controlling the epidemic. DiscussionTranslating science to policy to HIV service delivery is complex and vulnerable to significant delays. WHO, assuming a regulatory role, used preliminary Botswana Tsepamo study information regarding neural tube defects to issue a “safety signal” regarding DTG in May 2018. Regulatory evaluations of rare adverse reactions are complex, take time, and require considerable subject area specific expertise. After over a year, the WHO reversed its initial findings and issued revised treatment recommendations. However, the mixed messaging and confusion around dolutegravir’s safety profile has delayed national level adoption. The pace of national adoption of new WHO recommendations is measurable through published national guidelines and/or circulars available in the public domain. After 2015, published guidelines for 22 of 46 sub-Saharan countries (94% of 2018 regional HIV burden) showed that only three countries representing 4% of regional burden have adopted the new WHO preferred 1st line recommendations. ConclusionsMonitoring and evaluating the translation of science to service delivery is a critical element of successful disease control and elimination. The DTG false alarm and ongoing delayed access provides an opportunity to learn valuable lessons and implement corrective actions. However, lessons can only be learned by accurately describing and examining the timeline, processes, and impact of policy decisions that can adversely impact millions of people living with HIV. As with any successful global disease elimination effort or major project, it is important to establish a critical pathway for translation of science to service delivery and hold people and agencies accountable for their roles in accelerating and/or delaying progress.

Human immunodeficiency virus funding and access to treatment in sub-Saharan Africa

2021 ◽  
pp. 095646242110422
Author(s):  
Reuben Granich ◽  
Somya Gupta ◽  
Brian Williams
Keyword(s):  
Human Immunodeficiency Virus ◽  
Viral Suppression ◽  
Hiv Treatment ◽  
Sub Saharan Africa ◽  
People Living With Hiv ◽  
Access To Treatment ◽  
Immunodeficiency Virus ◽  
Sub Saharan ◽  
Living With Hiv ◽  
Hiv Funding

Human immunodeficiency virus (HIV) treatment prevents illness, death, and transmission. The 90-90-90 disease control target is only 73% of people living with HIV virally suppressed. For 2010 to 2019, we abstracted HIV funding data for 40 countries in sub-Saharan Africa (70% of global HIV burden and >99% of HIV burden in the region in 2018). During 2010–2019, there was ∼$52 billion funding for 40 countries (99% Africa HIV burden). Domestic funding ranged from $0 to $3.2 billion. PEPFAR funding was $32 billion (average $1.4 billion; range $0.089–4.3 billion) among 22 countries. Global Fund averaged $306 million ($1.9 million to $1.1 billion) for 40 countries. Among PLHIV, known HIV status averaged 80% (11% to 94%). ART coverage averaged 64% (9% to 90%). Viral suppression among PLHIV ranged from 8% to 87%. Of the 40 countries, 21 reported under 60% of PLHIV to be on treatment and 13 did not report viral suppression for 2018. Achieving 90-90-90 is feasible in challenging settings if resources are used efficiently. Despite the significant investment in the HIV response, many countries have not reached the 90-90-90 target. Greater attention to efficiency and prioritizing important targets will be required to end AIDS in Africa.

scholarly journals Aging, Health, and Quality of Life for Older People Living With HIV in Sub-Saharan Africa: A Review and Proposed Conceptual Framework

2017 ◽  
Vol 31 (1) ◽  
pp. 109-138 ◽  
Author(s):  
Mark J. Siedner
Keyword(s):  
Quality Of Life ◽  
Conceptual Framework ◽  
Care Delivery ◽  
Sub Saharan Africa ◽  
People Living With Hiv ◽  
Sub Saharan ◽  
Living With Hiv ◽  
The Impact

Objective: The number of people living with HIV (PLWH) over 50 years old in sub-Saharan Africa is predicted to triple in the coming decades, to 6-10 million. Yet, there is a paucity of data on the determinants of health and quality of life for older PLWH in the region. Methods: A review was undertaken to describe the impact of HIV infection on aging for PLWH in sub-Saharan Africa. Results: We (a) summarize the pathophysiology and epidemiology of aging with HIV in resource-rich settings, and (b) describe how these relationships might differ in sub-Saharan Africa, (c) propose a conceptual framework to describe determinants of quality of life for older PLWH, and (d) suggest priority research areas needed to ensure long-term gains in quality of life for PLWH in the region. Conclusions: Differences in traditional, lifestyle, and envirnomental risk factors, as well as unique features of HIV epidemiology and care delivery appear to substantially alter the contribution of HIV to aging in sub-Saharan Africa. Meanwhile, unique preferences and conceptualizations of quality of life will require novel measurement and intervention tools. An expanded research and public health infrastructure is needed to ensure that gains made in HIV prevention and treamtent are translated into long-term benefits in this region.

scholarly journals Stigmatising Attitudes Towards Co-workers with HIV in the Workplace of a Metropolitan State, Southwestern Nigeria

2017 ◽  
Vol 11 (1) ◽  
pp. 67-75 ◽  
Author(s):  
Idongesit Godwin Utuk ◽  
Kayode Omoniyi Osungbade ◽  
Taiwo Akinyode Obembe ◽  
David Ayobami Adewole ◽  
Victoria Oluwabunmi Oladoyin
Keyword(s):  
Sampling Technique ◽  
Sub Saharan Africa ◽  
Good Knowledge ◽  
People Living With Hiv ◽  
Cross Sectional Survey ◽  
Southwestern Nigeria ◽  
Cross Sectional ◽  
Sub Saharan ◽  
Living With Hiv ◽  
Hiv Aids

Background:Despite demonstrating global concerns about infection in the workplace, very little research has explored how co-workers react to those living with HIV in the workplace in sub-Saharan Africa. This study aimed to assess the level of stigmatising attitude towards co-workers living with HIV in the workplace.Methods:The study was a descriptive cross-sectional survey involving 403 respondents. They were recruited from selected companies through a multistage sampling technique. Survey was carried out using pre-tested semi-structured questionnaires. Data were analyzed using the Statistical Package for the Social Sciences to generate frequencies, cross tabulations of variables at 5% level of significance. Logistic regression model was used to determine the predictors at 95% confidence intervals.Results:Mean age of respondents was 32.9 ± 9.4 years with 86.1% being females. Overall, slightly below two-third (63.0%) had good knowledge on transmission of HIV/AIDS while 218 (54.1%) respondents had a high stigmatising attitude towards co-workers with HIV in the workplace. More female respondents (69.6%) demonstrated high stigmatising attitudes towards co-workers with HIV in the workplace (p = 0.012). Female workers were twice more likely to have high stigmatising attitudes towards co-worker with HIV [OR 2.1 (95% CI: 1.13 – 3.83)].Conclusion:Stigma towards people living with HIV/AIDs is still very persistent in different settings. Good knowledge amongst our participants about HIV/AIDs did not translate to low stigmatising attitudes among workers. Concerted efforts and trainings on the transmission of HIV/AIDs are essential to reduce stigma that is still very prevalent in workplace settings.

scholarly journals Synthesizing evidence on nutrition challenges among people living with HIV/AIDS in sub- Saharan Africa: a protocol for a scoping review

2019 ◽  
Vol 6 (7) ◽  
pp. 3173 ◽  
Author(s):  
Tafadzwa Dzinamarira ◽  
Moreblessing Chipo Mashora
Keyword(s):  
Health Outcomes ◽  
Scoping Review ◽  
Sub Saharan Africa ◽  
Future Research ◽  
People Living With Hiv ◽  
Nutritional Management ◽  
Sub Saharan ◽  
Living With Hiv ◽  
Improve Health ◽  
Hiv Aids

Background: Good nutritional status is highly significant for individuals who are infected with HIV. However, they still face a number of nutritional challenges. The proposed scoping review will map literature on the nutritional challenges facing people living with HIV/AIDS (PLWH) and guide future research in nutritional management to improve health outcomes for PLWH. Here we outline a scoping review protocol designed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P 2015 Guidelines).Methods: The Arksey and O’Malley’s 2005 scoping methodological framework further improved by Levac et al. 2010 will guide the search and reporting. Searches will be conducted for eligible articles from MEDLINE (PubMed), MEDLINE, CINAHL, Academic Search Complete and ISI Web of Science (Science Citation Index) electronic databases. Two independent reviewers will conduct the search guided by an inclusion and exclusion criteria. Quality appraisal of the included articles will be conducted guided by the mixed methods appraisal tool 2018 version. We will employ NVivo version 12 for thematic content analysis.Conclusions: The findings of this review will guide future research in nutritional management to improve health outcomes for PLWH in sub-Saharan African. This review will be disseminated electronically in a published peer reviewed article and in print.

Perpetuated HIV Microaggressions: A Novel Scale to Measure Subtle Discrimination Against People Living With HIV

2021 ◽  
Vol 33 (1) ◽  
pp. 1-15
Author(s):  
Marcie Berman ◽  
Lisa A. Eaton ◽  
Ryan J. Watson ◽  
Jessica L. Maksut ◽  
Katherine B. Rucinski ◽  
...  
Keyword(s):  
Convergent Validity ◽  
Discriminant Validity ◽  
Hiv Treatment ◽  
People Living With Hiv ◽  
Depressive Symptomology ◽  
Subtle Discrimination ◽  
Conspiracy Beliefs ◽  
Living With Hiv ◽  
Hiv Negative ◽  
Hiv Discrimination

HIV discrimination has served as a barrier to addressing the HIV epidemic and providing effective HIV treatment and care. Measuring HIV discrimination, particularly covert HIV discrimination, has proven to be complex. Adapted from a previous scale, we developed a perpetuated HIV micro-aggressions scale to assess covert forms of discriminatory beliefs among HIV-negative/unknown HIV status individuals. Factor analysis resulted in three subscales, explaining 73.58% of the scale's variance. The new scale demonstrated both convergent validity (HIV prejudice, HIV stereotypes) and discriminant validity (alcohol use, depressive symptomology). Perpetuated HIV microaggressions were significantly associated with HIV conspiracy beliefs, HIV prejudice, and HIV stereotypes. This new scale can serve as an important tool in evaluating perpetuated HIV microaggressions among HIV-negative individuals.

Sign in / Sign up

Export Citation Format

Share Document